How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,795 results for

Urine Uric Acid

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

321. Orange Juice And Sugar Intervention Study

lipoprotein cholesterol (LDL-C) [ Time Frame: 4 weeks ] Plasma LDL-C concentration Apolipoprotein B (apoB) [ Time Frame: 4 weeks ] Plasma apoB concentration Uric acid [ Time Frame: 4 weeks ] Plasma uric acid concentration de novo lipogenesis (DNL) [ Time Frame: 4 weeks ] %Fractional rate DNL Hepatic triglyceride [ Time Frame: 4 weeks ] %hepatic triglyceride Endogenous glucose production [ Time Frame: 4 weeks ] Endogenous glucose production during hyperinsulinemic clamp Secondary Outcome Measures (...) by University of California, Davis: orange juice sugar-sweetened beverage triglyceride low density lipoprotein cholesterol apolipoprotein B uric acid de novo lipogenesis hepatic triglyceride hepatic glucose production whole body insulin sensitivity Additional relevant MeSH terms: Layout table for MeSH terms Diabetes Mellitus Diabetes Mellitus, Type 2 Metabolic Syndrome Hypersensitivity Insulin Resistance Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Hyperinsulinism Immune System

2018 Clinical Trials

322. Effectiveness and Clinical Mechanism of Huanglian-Jiedu Decoction in Patients With Intense-exuberant Stomach Fire Syndrome

ratios in plasma [ Time Frame: Day 0,Day 5 ] Evaluation of oxidative stress parameters:SOD [ Time Frame: Day 0,Day 5 ] Evaluation of oxidative stress parameters:MDA [ Time Frame: Day 0,Day 5 ] Pyruvate Acid / Uric Acid ratios in plasma [ Time Frame: Day 0,Day 5 ] Mass Spectrometry analyses for urine sample [ Time Frame: Day 0,Day 5 ] Mass Spectrometry analyses for urine sample include hypoxanthine, 1.7 - diphosphate sedoheptose, -5- riboflavin phosphate, urobilin, D - Ribose, ubiquinone, urinary (...) that described in traditional Chinese medicine. The basic symptoms included feverish sensation, thirst that preferring cold drink, bad breath, flushed face, bound stool, scanty yellowish urine, red tongue with dry and yellowish fur, and the forceful or rapid pulse. The disease-specific symptoms included tooth or/and gums for acute pericoronitis, ulcer for recurrent aphthous stomatitis and herpes for recurrent herpes simplex labialis. Each symptom was assessed by the Visual Analogue Scale(VAS),where a higher

2018 Clinical Trials

323. A Clinical Study Evaluating the Efficacy and Safety of RPh201 Treatment in Individuals With Alzheimer's Disease With or Without Coexisting Cerebrovascular Disease

] Clinical Laboratory Assessments - (blood and urine) at at Month 6 [ Time Frame: Month 6 ] Chemistry: alkaline phosphatase, albumin, blood urea nitrogen, calcium, chloride, creatinine, glucose (random), inorganic phosphorus, potassium, alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transpeptidase, lactate dehydrogenase, sodium, direct bilirubin, total bilirubin, total protein, amylase, uric acid Hematology: haemoglobin, hematocrit, red blood cell count, white blood cell (WBC) count (...) dehydrogenase, sodium, direct bilirubin, total bilirubin, total protein, amylase, uric acid Hematology: haemoglobin, hematocrit, red blood cell count, white blood cell (WBC) count, WBC differential (absolute counts), numerical platelet count Urinalysis: specific gravity, pH, ketones, glucose, nitrite, blood, leukocyte esterase, protein, urobilinogen, bilirubin If nitrite, blood, or protein tests are positive, a microscopic examination will be performed Vital Signs [ Time Frame: Month 12 ] Vital signs

2018 Clinical Trials

324. Study in Patients With Tumours Requiring Arginine to Assess ADI-PEG 20 With Atezolizumab, Pemetrexed and Carboplatin

within 28 days prior to cycle 1 day 1 as defined by the following: Haemoglobin (HB) > 9.0 g/dL Absolute neutrophil count (ANC) > 1.5 x 109/L. Platelets > 75 x 109/L. Either: (i) serum bilirubin ≤ 1.5 x upper limit of normal (ULN) or (ii) alanine aminotransferase (ALT), aspartate aminotransferase (AST) and/or alkaline phosphatase (ALP) ≤ 3 x (ULN) unless raised due to tumour in which case up to 5 x ULN is permissible. Serum uric acid ≤ 10 mg/dL (595 µmol/L) (with or without medication control (...) ) and male patients with female partners of childbearing potential and their partners must agree to use a highly effective form of contraception for the duration of the study and until 35 days after the final dose of ADI-PEG 20 or 180 days after the final dose of atezolizumab, pemetrexed or carboplatin, whichever is later. Negative serum or urine pregnancy test for female patients of childbearing potential within 14 days prior to cycle 1 day 1. Adequate normal organ, marrow and coagulation function

2018 Clinical Trials

325. A Single Oral Dose Study to Evaluate Four Different Formulations of AZD9977 and the Effect of Food in Healthy Male Subjects

as a variable of safety and tolerability after administration of single oral dose of AZD9977 capsule, ER capsules (fast rate and Int. rate) and oral suspension (reference). Laboratory assessments: Serum Clinical chemistry - Urea and Uric acid [ Time Frame: At screening, dosing sessions of Part A and Part B and follow-up (5 to 7 days after final dose) ] To assess serum urea and uric acid level as a variable of safety and tolerability after administration of single oral dose of AZD9977 capsule, ER capsules (...) serum NT-proBNP level as a variable of safety and tolerability after administration of single oral dose of AZD9977 capsule, ER capsules (fast rate and Int. rate) and oral suspension (reference). Laboratory assessments: Clinical Urinalysis - Glucose [ Time Frame: At screening, dosing sessions of Part A and Part B and follow-up (5 to 7 days after final dose) ] To assess urine glucose level as a variable of safety and tolerability after administration of single oral dose of AZD9977 capsule, ER capsules

2018 Clinical Trials

326. Phase 2 Study of TMX-049 in Subjects With Type 2 Diabetes and Albuminuria

in serum uric acid (sUA) [ Time Frame: 12 Weeks ] Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years (...) uric acid-lowering therapy within previous 2 weeks History of intolerance to any XO inhibitor History of a gout flare requiring pharmacologic treatment History or presence of tophaceous gout History of immunosuppressant treatment for any known or suspected renal disorder History of a non-diabetic form of renal disease Glycosylated hemoglobin (HbA1c) >11% sUA <4.0 mg/dL or >10.0 mg/dL Positive urinary pregnancy test Dialysis for acute renal failure within previous 6 months Renal allograft in place

2018 Clinical Trials

327. Effect of Time-Restricted Feeding on Fat Loss and Cardiometabolic Risk Factors in Overweight Adults

abundance. Effect of weight loss on several biomarkers related to kidney stones. The primary endpoint for this ancillary study is urinary oxalate, and the secondary endpoints are urinary citrate, chloride, sodium, potassium, calcium, phosphorus, uric acid, and creatinine. Effect of meal timing on blood pressure regulation and kidney function. The primary endpoints of this ancillary study include urinary aldosterone excretion, sodium, potassium, and endothelin, whereas the secondary endpoints include (...) ] 24-hour urinary oxalate, citrate, sodium, calcium, chloride, potassium, and creatinine, as measured in mg/day 24-hour urinary phosphorus and uric acid [ Time Frame: 14 weeks ] 24-hour urinary phosphorus and uric acid, as measured in g/day 24-hour urinary aldosterone excretion [ Time Frame: 14 weeks ] 24-hour urinary aldosterone excretion (µg/12 hr) 12-hour urinary sodium and potassium [ Time Frame: 14 weeks ] 12-hour urinary sodium and potassium (mmol/12 hr) 12-hour urinary endothelin [ Time

2018 Clinical Trials

328. Contrast Nephropathy in Type 2 Diabetes

radiocontrast material for any medical indication in Fayoum universiy hospital will be selected. There will be two arms of the study,each arm will contain 20 patients first arm diabetics on linagelptin, second arm diabetics on other DPP4 inhibitors. Data collection: Patients will be subjected to; full clinical examination,waist hip ratio assessment,BMI assessment fasting blood glucose,Serum uric acid, urine ACR, eGFR will be done before and after the investigation. Study Design Go to Layout table for study (...) to Primary Outcome Measures : affection of estimated glomerular filtration rate [ Time Frame: Two months ] A significant decrease in estimated glomerular filtration rate (eGFR) Secondary Outcome Measures : change in serum uric acid [ Time Frame: Two months ] A significant rise in serum uric acid Other Outcome Measures: Affection of albumin creatinine ratio [ Time Frame: Two months ] A significant increase in albumin creatinine ratio in urine (ACR) Eligibility Criteria Go to Information from the National

2018 Clinical Trials

329. A Trial of Cardiac Injections of iMP Cells During CABG Surgery

hours) and at 1 week, 30 days, 6 months and 12 months post surgery. ] Blood biomarkers related to cardiac function. Routine - Urea and electrolytes, liver function tests and full blood count. Exploratory - Uric acid, lipid profile, high sensitivity C reactive protein, high sensitivity troponin, N terminal pro brain natriuretic peptide. Levels compared between the two groups. Blood test - Assessment of immunogenicity [ Time Frame: Baseline and 30 days post surgery. ] Humoral response assay to assess (...) , a urine test, health questionnaires and a discussion about the participant's health and any adverse events. Specific details are available from the chief investigator, see below. The 6 month visit will also involve a follow up LGE-MRI for primary endpoint assessment. After 12 months, participation in the study will end and participants will receive only the normal post CABG care. As this is a quadruple blind randomised controlled trial, neither participants nor care staff will know to which group

2018 Clinical Trials

330. Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

. Usage of non-steroidal anti-inflammatory medications (NSAIDS) for the treatment of osteoarthritis and uric acid synthesis inhibitors for the treatment of gout are permitted. Patients with any serious and/or uncontrolled concurrent medical conditions (e.g. active or uncontrolled infection, uncontrolled diabetes) or psychiatric illness that could, in the investigator's opinion, cause unacceptable safety risks or potentially interfere with the completion of the treatment according to the protocol (...) of Bladder Tumor [TURBT] may be used) and at time of RC. Peripheral blood and urine samples are also required. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 43 participants Allocation: Non-Randomized Intervention Model: Sequential Assignment Intervention Model Description: Cohort 1: Nivolumab alone. In the absence of the occurrence of high rate of treatment related adverse events, the study will proceed with enrollment

2018 Clinical Trials

331. A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity of N-Rephasin® SAL200 in Healthy Male Volunteers

, monocyte, eosinophil, basophil), RBC, hemoglobin, hematocrit, platelets) coagulation values(PT(INR), aPTT) serum biochemical values(calcium, phosphorus, glucose, BUN, uric acid, cholesterol, total protein, albumin, total bilirubin, alkaline phosphatase, AST, ALT, γ-GT, CPK, LDH, creatinine, sodium, potassium, chloride, triglyceride, amylase, lipase, ESR, hs-CRP) urinalysis values(color, pH, specific gravity, albumin, bilirubin, glucose, urobilinogen, ketone, nitrite, occult blood, leukocyte, microscopy (...) ) urine drug screening values(amphetamine, barbiturates, benzodiazepines, cannabinoids, cocaine, cotinine, opioids) serological values(HBsAg, anti-HCV Ab, anti-HIV Ab, RPR) will be analyzed by the clinical laboratory Evaluation of the safety of N-Rephasin® SAL200 in healthy human volunteers by allergenicity test [ Time Frame: Up to 50 days after administration ] Allergenicity test will be performed by standard allergy skin test Evaluation of the safety of N-Rephasin® SAL200 in healthy human volunteers

2018 Clinical Trials

332. A Phase I Study of LuoXin Innovate (LXI-15028) in Healthy Chinese Subjects to Evaluate the Pharmacokinetics, Safety and Tolerability.

phosphatase (ALP), aspartate aminotransferase (AST), alanine aminotransferase (ALT), glutamyltransferase (γ-GT), magnesium, sodium, potassium, chlorine, total calcium, inorganic phosphorus, lactate dehydrogenase (LDH), glucose, uric acid, triglyceride (TG); and list all the result. Adverse events of single dose [ Time Frame: Up to 3 weeks ] The adverse events are encoded using MedDRA 20.1. According to system organ classification (SOC) and preferred term (PT), all TEAE, investigational drug-related TEAE (...) , total bilirubin, Conjugated bilirubin, creatinine, creatine kinase (CPK), alkaline phosphatase (ALP), aspartate aminotransferase (AST), alanine aminotransferase (ALT), glutamyltransferase (γ-GT), magnesium, sodium, potassium, chlorine, total calcium, inorganic phosphorus, lactate dehydrogenase (LDH), glucose, uric acid, triglyceride (TG); and list all the result. Adverse events of multiple doses [ Time Frame: Up to 6 weeks ] The adverse events are encoded using MedDRA 20.1. According to system organ

2018 Clinical Trials

333. Study Evaluating Subjects With Distal Renal Tubular Acidosis

potassium ≥ 3.0 mEq/L on alkali therapy and potassium supplementation (if indicated) on at least one occasion for each within 6 months prior to Visit 1; Exclusion Criteria: Female subject who is pregnant or lactating or has plans for pregnancy during the study; Subject has evidence of proximal tubule dysfunction (eg, hypophosphatemia, low serum uric acid, glycosuria, or amino aciduria); Subject presents with another diagnosed condition as a potential etiology for her/his dRTA (eg, systemic lupus (...) with a previous diagnosis of primary dRTA of at least 4 months duration for subjects < 12 years of age, and at least one year for those ≥ 12 years of age, based on documented history of non-anion gap, hyperchloremic, hypokalemic metabolic acidosis; Subject requires ≥ 0.9 mEq/kg/day of alkali therapy to maintain serum bicarbonate levels above the LLN for the laboratory providing results; Urine pH > 5.5; serum bicarbonate > 18 mEq/L for subjects ≥ 4 years old or > 17 mEq/L for subjects < 4 years old; and serum

2018 Clinical Trials

334. A Safety and Tolerability Study of RJX Drug Product in Healthy Participants

chemistry parameters include: albumin, total protein, glucose, sodium, magnesium,potassium, chloride, carbon dioxide, creatinine, aspartate transaminase, alanine aminotransferase, alkaline phosphatase, gamma glutamyl transferase, high density lipoprotein, total bilirubin, triglyceride, total cholesterol, lactate dehydrogenase, calcium, uric acid and blood urea nitrogen. Observed values and actual changes from baseline of continuous clinical chemistry parameters will be summarized descriptively (...) density lipoprotein, total bilirubin, triglyceride, total cholesterol, lactate dehydrogenase, calcium, uric acid and blood urea nitrogen. Observed values and actual changes from baseline of continuous clinical chemistry parameters will be summarized descriptively, by actual treatment/dose level and visit/time point. Categorical outcomes will be summarized by frequency tabulations. Part 1: Number of participants with hematology values of potential clinical importance criteria (PCC). [ Time Frame: Up

2018 Clinical Trials

335. Preventive Fenestration With and Without Clipping in Kidney Transplantation

Nitrogen Level (mg/dL) Plasma uric acid Level [ Time Frame: 6 months ] Plasma uric acid Level (mg/dL) Serum creatinine level [ Time Frame: 6 months ] Serum creatinine level (mg/dL) Rate of delayed graft function [ Time Frame: 30 days ] Is defined as the need for one or more hemodialysis treatments following transplantation prior to the onset of graft function. Glomerular filtration rate [ Time Frame: 6 months ] GFR (mL/min/1.73 m2) calculated with "175 × (Scr)-1.154 × (Age)-0.203 × (0.742 if female (...) is not blood, pus, or urine will be monitored Lymphocele size [ Time Frame: 6 months ] Lymphocele diameter and volume will be recorded by ultrasound examination in mL. Lymphocele symptomes [ Time Frame: 6 months ] Lymphocele/lymphorrhea severity grade [ Time Frame: 6 months ] Severity of lymphocele/lymphorrhea will be graded based on the applied management strategy (Grade A: Observation, Grade B: Non-surgical intervention, Grade C: Surgery). Blood Urea Nitrogen Level [ Time Frame: 6 months ] Blood Urea

2018 Clinical Trials

336. ACEI/CCB Versus ACEI/DIU Combination Antihypertensive Therapy in Chinese Hypertensive Patients (ACvAD)

pressure; liver function (ALT, AST, TBL) results ≥ Twice the upper limit, serum creatinine ≥1.5mg/dl (133μmol/L), urine routine protein (+) or higher; blood potassium>5.5mmol/L or <3.5mmol/L; history of gout or male blood uric acid ≥420μmol/L, female ≥360μmol/L; elderly nursing home patients; or patients who are participating in other clinical trials. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study

2018 Clinical Trials

337. A Study of Autologous Induced Islet Body With Type 1 Diabetes

in the last year; patients are not guaranteed to take effective contraceptive measures during the trial; patients were diagnosed as tumor or tumor chemotherapy, radiotherapy and acute uric acid nephropathy within 5 years. Other circumstances that researchers do not consider suitable for research. Withdrawal from trial, loss of follow-up or death due to other reasons Incomplete data, affecting effectiveness and safety judges Researchers believe that the need for termination of the trial is needed. Contacts (...) , CIK, T, NK, and Car T products with CD19 or other targets) Patients with severe cardiovascular and cerebrovascular disease (NYHA class 3-4) cannot cooperate with the study Patients with severe liver dysfunction(liver function AST and ALT exceeded 2.5 times the normal upper limit). Patients with kidney disease or moderate to severe renal insufficiency (renal function eGFR <60 ml/min/1.73 m2) Women in pregnancy (urine/blood pregnancy test positive) or lactation; men or women with pregnancy plans

2018 Clinical Trials

338. A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients

: at scheduled visits from randomisation to 3months after treatment discontinuation. ] Data for urea nitrogen recorded in the eCRF will be listed and summarized by treatment group and visit. Change in Uric acid (mmol/L) [ Time Frame: at scheduled visits from randomisation to 3months after treatment discontinuation. ] Data for uric acid recorded in the eCRF will be listed and summarized by treatment group and visit. Change in absolute neutrophil count (/L) [ Time Frame: at scheduled visits from randomisation (...) disocontinuation, assessed up to 65months ] Data for blood testing recorded in the eCRF will be listed and summarized by treatment group and visit. Urinalysis: Change in color and apprearance [ Time Frame: at screening and as clinical needed before treatment disocontinuation, assessed up to 65months ] color and apprearance of urine recorded in the eCRF will be listed and summarized by treatment group and visit. Urinalysis: Change in ketones (mmol/L) [ Time Frame: at screening and as clinical needed before

2018 Clinical Trials

339. Metformin Plus/Minus Fasting Mimicking Diet to Target the Metabolic Vulnerabilities of LKB1-inactive Lung Adenocarcinoma

significant potassium within the normal limits, or corrected with supplements glomerular filtration rate (GFR) > 60 ml/min as estimated on the basis of 24 h urine collection and analysis, The GFR will be also calculated with the Cockroft-Gault formula on the basis of blood creatinine levels blood uric acid < 10 mg/dl ALT and AST ≤ 2.5 x ULN (Upper Limit of Normal). In the case of documented liver metastases, a threshold of ALT and AST ≤ 5 x ULN will be considered acceptable total bilirubin < 1.5 ULN (...) treatment on overall survival, objective response rate, adverse events, systemic metabolic parameters (plasma glucose, amino acids, lipid profile). Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 88 participants Allocation: Randomized Intervention Model: Parallel Assignment Intervention Model Description: Single Institution, open-labeled, double arm, non-comparative, randomized, single stage phase II trial, with "pick-the-winner

2018 Clinical Trials

340. Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamic Effect of Different Concentrations of a New Anti-inflammatory Substance in Subjects With Chronic Plaque Psoriasis

differentials, measure in SI units Change from baseline to Day 4, Day 8 and Day 12 in clinical chemistry parameters [ Time Frame: Up to Day 12 ] sodium, potassium, chloride, bicarbonate, blood urea nitrogen, glucose, aspartate aminotransferase (AST), alanine aminotransferase (ALT), gammaGT, uric acid, calcium, phosphate, albumin, triglycerides, cholesterol, lactate dehydrogenase, total protein, creatinine, total bilirubin, direct bilirubin, indirect bilirubin Change from baseline to Day 4, Day 8 and Day 12 (...) in urinalysis parameters [ Time Frame: Up to Day 12 ] Single parameters only to be listed if deviation from usual urine dip test, e.g., sediment, leucocytes, nitrite, pH, protein, glucose, ketones, urobilinogen, bilirubin, blood/haemoglobin Number of subjects with abnormal clinical significant ECG evaluation [ Time Frame: Up to Day 12 ] Evaluation of 12-lead ECG (overall evaluation, assessed by investigator as 'normal', 'abnormal not clinically significant', 'abnormal clinically significant') Number

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>